Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 263 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nebulizer Clear all
Recruiting Phase 1 Interventional

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

NCT07372989
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Matrix
Biological
Lead sponsor
Maule Stem Cell Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 12:16 AM EDT
Terminated Not applicable Interventional Results available

Analysis of Lipid Biomarkers of Exposure and Host Response

NCT00493831
View directory record Official record
Conditions
Cigarette Smoking
Interventions
nicotine polacrilex, transdermal system or inhaler
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Not applicable Interventional Results available

Aides in Respiration Health Coaching for COPD

NCT02234284
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Health Coaching
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 95 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 23, 2026, 12:16 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

High Flow Nasal Cannula Rates in Pediatric Asthma

NCT06379607
View directory record Official record
Conditions
Pediatric Asthma
Interventions
"High Flow" High Flow Nasal Cannula, "Low Flow" High Flow Nasal Cannula
Device
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558
View directory record Official record
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

NCT03421730
View directory record Official record
Conditions
Wheezing, Reactive Airway Disease, Mild Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
4 Years to 8 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Nasal Insulin to Fight Forgetfulness - Device Study

NCT03857321
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
Insulin, Placebo, intranasal nebulizer-like device
Drug · Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

NCT05737485
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
RCT1100
Drug
Lead sponsor
ReCode Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects

NCT01617369
View directory record Official record
Conditions
Healthy Subjects
Interventions
Hypertonic Saline
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 4 Interventional Results available

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

NCT02420015
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Nicotine replacement therapy, Bupropion, cognitive-behavioral smoking cessation counseling, Mobile Contingency Management, Stay Quit Coach, SMS text messaging
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 4 Interventional Results available

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

NCT02995915
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring
Other · Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 23, 2026, 12:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

NCT04648826
View directory record Official record
Conditions
Sarcomas, Melanomas, Germ Cell Tumors, Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas), Pulmonary Metastases
Interventions
AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine
Device · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 23, 2026, 12:16 AM EDT
Available No phase listed Expanded access

Molgramostim Nebulizer Solution Expanded Access Program Protocol

NCT06546098
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim nebulizer solution
Drug
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
U.S. locations
11
States / cities
Los Angeles, California • Gainesville, Florida • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Results available

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)

NCT00147199
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled treprostinil, Placebo inhalation solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial

NCT02885636
View directory record Official record
Conditions
Congestive Heart Failure, Heart Failure, Left-Sided, Left-Sided Heart Failure
Interventions
Albuterol, Saline placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Normal Breathing and Swallowing in Healthy Volunteers

NCT03122145
View directory record Official record
Conditions
Healthy
Interventions
Capsaicin, Videofluoroscopic swallow study
Drug · Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 1 Interventional

Iloprost Effects on Gas Exchange and Pulmonary Mechanics

NCT01274481
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Pulmonary Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 10, 2012 · Synced Oct 23, 2026, 12:16 AM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 23, 2026, 12:16 AM EDT
Not listed Phase 4 Interventional

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography

NCT01361984
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis
Interventions
Nebulized arformoterol, Salmeterol
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 23, 2026, 12:16 AM EDT
Not listed Early Phase 1 Interventional

Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy

NCT00536952
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pulmozyme, Placebo, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Oct 23, 2026, 12:16 AM EDT
Completed Phase 1 Interventional Results available

Inhaled Tobramycin in BPD

NCT04560179
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose, Tobramycin solution for inhalation 300mg dose
Drug
Lead sponsor
Erik Allen Jensen
Other
Eligibility
4 Weeks and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 23, 2026, 12:16 AM EDT
Terminated Phase 2Phase 3 Interventional

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

NCT04360096
View directory record Official record
Conditions
SARS-CoV 2, COVID, ARDS, ALI, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Dyspnea
Interventions
ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo
Drug · Device
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 23, 2026, 12:16 AM EDT
Not listed Phase 1 Interventional

Comparison of Bronchodilator Response From Three Different Aerosol Delivery Methods in Patients With COPD Using Hyperpolarized Xe 129 MRI Ventilation Imaging

NCT06271408
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Vibrating Mesh Nebulizer, Metered Dose Inhaler, Jet Nebulizer
Drug · Device
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 23, 2026, 12:16 AM EDT